TG Therapeutics (US:TGTX) — Company Overview, News & Financial Data
TG Therapeutics focuses on therapies for hematologic malignancies and autoimmune diseases, advancing next-generation treatments.
About TG Therapeutics
TG Therapeutics (NASDAQ:TGTX) is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of hematologic malignancies and autoimmune diseases. Their pipeline consists of innovative, novel treatments aimed at improving the quality of life for patients with B-cell malignancies and autoimmune diseases. With a commitment to addressing unmet medical needs, TG Therapeutics is dedicated to advancing its research and development projects to bring next-generation therapies to the market. Targeting specific diseases with precision medicine, their objective is to provide more effective and less toxic treatment options, spearheading a new era in patient care.
Snapshot
Operations
Products and/or services of TG Therapeutics
- UKONIQ (umbralisib), an innovative treatment for marginal zone lymphoma and follicular lymphoma.
- BET Inhibitors, a novel class targeting hematologic malignancies and autoimmune diseases.
- Anti-CD47 Monoclonal Antibody, aimed at enhancing the immune system's ability to fight cancer.
- MS Therapeutics, focusing on novel treatments for multiple sclerosis.
- PI3K Delta Inhibitor Program, targeting a range of hematologic cancers.
- BTK Inhibitor Program, aimed at developing next-generation therapies for B-cell malignancies.
TG Therapeutics executive team
- Mr. Michael S. Weiss Esq., J.D.Chairman, CEO & President
- Mr. Sean A. Power CPACFO, Corporate Secretary & Treasurer
- Ms. Jenna BoscoSenior Vice President of Corporate Communications
- Mr. Adam WaldmanChief Commercialization Officer